AngioDynamics (FRA:UG2) ROCE %: -12.96% (As of Feb. 2026)


FRA:UG2 AngioDynamics Inc FRA:UG2
62 GF Score
Price €10.80
GF Value €7.27
! 7 Warning Signs
View Full Analysis

What is AngioDynamics ROCE %?

AngioDynamics FRA:UG2 -0.92% 62 ROCE % is -12.96% as of Feb. 2026. GuruFocus rates FRA:UG2 with a GF Score™ of 62/100 and a GF Value™ of €7.27. The stock has 7 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. AngioDynamics's annualized ROCE % for the quarter that ended in Feb. 2026 was -12.96%.

AngioDynamics  (FRA:UG2) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

AngioDynamics ROCE % Related Terms

AngioDynamics ROCE % Historical Data

* Premium members only.

The historical data trend for AngioDynamics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AngioDynamics ROCE % Chart

AngioDynamics Annual Data
Trend May16 May17 May18 May19 May20 May21 May22 May23 May24 May25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.35 -3.97 -3.97 -10.06 -10.93

AngioDynamics Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13.08 -6.78 -15.49 -5.06 -12.96
FRA:UG2
62GF Score
AngioDynamics Inc FRA:UG2
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AngioDynamics ROCE % Calculation

AngioDynamics's annualized ROCE % for the fiscal year that ended in May. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: May. 2025 )  (A: May. 2024 )(A: May. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: May. 2025 )  (A: May. 2024 )(A: May. 2025 )
=-21.343/( ( (293.846 - 84.318) + (248.488 - 67.587) )/ 2 )
=-21.343/( (209.528+180.901)/ 2 )
=-21.343/195.2145
=-10.93 %

AngioDynamics's ROCE % of for the quarter that ended in Feb. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Feb. 2026 )  (Q: Nov. 2025 )(Q: Feb. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Feb. 2026 )  (Q: Nov. 2025 )(Q: Feb. 2026 )
=-21.756/( ( (233.274 - 62.248) + (220.534 - 55.892) )/ 2 )
=-21.756/( ( 171.026 + 164.642 )/ 2 )
=-21.756/167.834
=-12.96 %

(1) Note: The EBIT data used here is four times the quarterly (Feb. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -12.96% mean?
AngioDynamics (FRA:UG2) has a ROCE % of -12.96% as of Feb. 2026.
Is AngioDynamics' ROCE % too high?
AngioDynamics' current ROCE % is -12.96%. Overall, AngioDynamics has a GF Score™ of 62/100, reflecting its overall financial health beyond just this single metric.
How does AngioDynamics' ROCE % compare to OSUR and UTMD?
AngioDynamics' ROCE % of -12.96% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AngioDynamics's current ROCE % is -12.96%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AngioDynamics stock overvalued right now?
AngioDynamics (FRA:UG2) has a current ROCE % of -12.96%. The stock's GF Value™ is €7.27, compared to a current price of €10.80 — trading 48.6% above its estimated fair value. The current ROCE % is -12.96%. AngioDynamics' overall GF Score™ is 62/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For AngioDynamics (FRA:UG2), the current ROCE % is -12.96% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AngioDynamics (FRA:UG2) Overvalued in 2026?

Based on GuruFocus' analysis, AngioDynamics stock appears to be overvalued. The current stock price of €10.80 is trading 48.6% above its estimated GF Value™ of €7.27.

Key valuation signals for FRA:UG2:

  • ROCE %: -12.96%
  • GF Value™: €7.27 vs. price of €10.80 (48.6% above fair value)
  • GF Score™: 62/100 with 7 warning signs

No single metric tells the full story. See the FRA:UG2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AngioDynamics Business Description

Other Exchanges ANGO:USA
Address 14 Plaza Drive, Latham, NY, USA, 12110
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
62GF Score

Get the complete analysis for FRA:UG2

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€10.80
Price
€7.27
GF Value